Boy, 13, Has No Reproductive OrgansAllAfrica.comA medical evaluation by an IndianHospital in Abuja sent to FortisEscortsHospital, New delhi, India, from the Department of Surgery, Federal Medical Centre, QueenElizabethHospital, Umuahia, explained that …
A hidden heart disease that's often misdiagnosed – Boston Globe
Boston Globe |
A hidden heart disease that’s often misdiagnosed
Boston Globe Two years ago, Thomas Fiorito, 59, was told to get his affairs in order by his doctors at Emory University Hospital in Atlanta; his amyloidosis was causing severe heart failure that would likely kill him in a few months. Like Cohen, his doctors also … Amyloidosis: A hidden cause of heart failure that’s often underdiagnosedBoston.com |
Biogen Idec presenterà all'ECTRIMS numerosi nuovi dati relativi alla suo ampia … – Teleborsa
Teleborsa |
Biogen Idec presenterà all’ECTRIMS numerosi nuovi dati relativi alla suo ampia …
Teleborsa PROCESSO DACLIZUMAB AD ELEVATO RENDIMENTO (DAC HYP): in fase di sviluppo come iniezione sottocutanea da somministrare mensilmente. Si ritiene che DAC HYP abbia come target le cellule immunitarie attive che possono giocare un ruolo … |
Iran reportedly producing deadly sarin gas – Daily Caller
Iran reportedly producing deadly sarin gasDaily CallerAt this facility, the regime produces five gases: sarin, phosphor chlorine, phosgene oxcime or CX (a potent gas with immediate effects on the skin and respiratory organs), mustard and nitrogen musta…
Enbrel, Humira "still mainstay" first-line US RA biologics – PharmaTimes
Enbrel, Humira “still mainstay” first-line US RA biologics
PharmaTimes In addition, treating physicians told the study that they would consider switching 22%-34% of their patients who are currently being treated with Orencia IV, and 20%-25% of their patients who are receiving Genentech/Biogen Idec’s Rituxan (rituximab) or … |
Biogen Idec présentera de nouvelles données approfondies de son portefeuille … – BFMTV.COM
Biogen Idec présentera de nouvelles données approfondies de son portefeuille …
BFMTV.COM PROCESSUS À HAUT RENDEMENT DU DACLIZUMAB (DAC HYP – DACLIZUMAB HIGH-YIELD PROCESS) : une thérapie d’injection sous-cutanée mensuelle en cours d’élaboration. Le DAC HYP semble cibler les cellules immunitaires activées qui peuvent … |
Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis … – Financial Post
Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis …Financial PostDACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): is being developed as a once-monthly subcutaneous injection. DAC HYP is believed to target the activated immune cells…
Biogen Idec stellt umfangreiche neue Daten zu seinem robusten Portfolio für … – Finanzen.net
Biogen Idec stellt umfangreiche neue Daten zu seinem robusten Portfolio für …
Finanzen.net DACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): Dieser Wirkstoff wird als einmal monatlich verabreichte subkutane Injektion entwickelt. Es wird angenommen, dass DAC HYP auf die aktivierten Immunzellen abzielt, die eine sehr wichtige Rolle bei MS … |
Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis … – Wall Street Journal
Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis …Wall Street JournalDACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): is being developed as a once-monthly subcutaneous injection. DAC HYP is believed to target the activated immune …
Biogen Idec presenterà all'ECTRIMS numerosi nuovi dati relativi alla suo ampia … – ANSA.it
Biogen Idec presenterà all’ECTRIMS numerosi nuovi dati relativi alla suo ampia …
ANSA.it PROCESSO DACLIZUMAB AD ELEVATO RENDIMENTO (DAC HYP): in fase di sviluppo come iniezione sottocutanea da somministrare mensilmente. Si ritiene che DAC HYP abbia come target le cellule immunitarie attive che possono giocare un ruolo … |